ReviewHematology. American Society of Hematology. Education Program2016
Thrombosis in the setting of cancer.
Review in Hematology. American Society of Hematology. Education Program, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- Review
- Interplay of genetic and clinical factors in cancer-associated thrombosis: Deciphering the prothrombotic landscape of colorectal cancer.World journal of gastroenterology · 2025Review
- Inpatient Outcomes of Cerebral Venous Thrombosis in Patients With Malignancy Throughout the United States.Journal of stroke · 2024Article
- The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.Journal of blood medicine · 2024Review
- Implementation of a cancer-associated thrombosis prevention program at a rural cancer center.Research and practice in thrombosis and haemostasis · 2024Article
- Trajectories of adherence to extended treatment with direct oral anticoagulants and risks of recurrent venous thromboembolism and major bleeding.Journal of managed care & specialty pharmacy · 2023Article
- Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism.Clinical and translational science · 2023Article
- New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism.Drug design, development and therapy · 2022Review
- Coagulopathies in Intensive Care Medicine: Balancing Act between Thrombosis and Bleeding.Journal of clinical medicine · 2021Review
- Heparin and Derivatives for Advanced Cell Therapies.International journal of molecular sciences · 2021Review
- Systemic coagulation is activated in patients with meningioma and glioblastoma.Journal of neuro-oncology · 2021Article
- Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?Journal of neuro-oncology · 2021Article
- Survival of patients with cancer associated thrombosis at the Uganda Cancer Institute.Ecancermedicalscience · 2021Review
- Update on Guidelines for the Management of Cancer-Associated Thrombosis.The oncologist · 2021Review
- Sequelae of Anticoagulant Therapy in a Patient with History of Pulmonary Malignancy: A Case Report.Clinical practice and cases in emergency medicine · 2020Article
- Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.Leukemia · 2019Article
- Cancer-associated thrombosis: The search for the holy grail continues.Research and practice in thrombosis and haemostasis · 2018Review
- New Interfaces of Thyroid Hormone Actions With Blood Coagulation and Thrombosis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Review
- Therapeutic Anticoagulation in Patients with Primary Brain Tumors or Secondary Brain Metastasis.The oncologist · 2018Review
- Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.Blood advances · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is a common cause of adverse outcomes in patients with cancer. The risk of VTE varies with cancer type, stage and grade, cancer therapy, and supportive care, as well as patient characteristics including age, ethnicity, and inherited and acquired comorbid conditions. VTE prophylaxis should be provided to all hospitalized cancer patients and high-risk outpatients. Low-molecular-weight heparin (LMWH) remains the first-line therapy for VTE in patients with active cancer. Anticoagulation should be continued as long as there is evidence of active disease or patients are receiving cancer treatment. The efficacy of direct oral anticoagulants in the treatment of cancer-associated thrombosis remains incompletely defined. Central venous catheter (CVC)-associated VTE should be treated with anticoagulation alone, unless the CVC is no longer required. Recent studies indicate that anticoagulation may be appropriate for patients with persistent thrombocytopenia or solid tumor brain metastases. Management of recurrent VTE includes the identification of the cause(s) of the recurrence and solutions targeted at addressing the potential precipitants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.